Sichuan Hebang Biotechnology Corporation Limited
603077.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.83B
Close$
$-0.01
100.5% downside
Current Fair Value
100.5% downsideOvervalued by 100.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.83 Billion |
|---|---|
| Enterprise Value | $19.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.07 |
| Beta | 0.41 |
| Outstanding Shares | 8,134,462,590 |
Return
| Return on Equity | -1.08% |
|---|---|
| Return on Assets | -0.70% |
| Return on Invested Capital | -0.42% |
Valuation & Multiples
| P/E Ratio | -83.52 |
|---|---|
| PEG | -19.59 |
| Price to Sales | - |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | 3.17 |
| Enterprise Value to EBIT | -172.63 |
| Enterprise Value to Net Income | -94 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.80 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sichuan Hebang Biotechnology Corporation Limited
5,085 employees
CEO: Xiaoping Zeng Headquartered in Chengdu, China, Sichuan Hebang Biotechnology Corporation Limited, which originated in 2002, operates as a multifaceted enterprise. The company's core activities revolve around the development and distribution of products...